Quantcast
Last updated on April 20, 2014 at 8:19 EDT

Latest linezolid Stories

2008-10-22 00:00:05

SAN DIEGO, Oct. 22 /PRNewswire/ -- Trius Therapeutics, Inc., today announced the award of a $28 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, for the development of novel antibiotics directed against multiple Gram-negative bacterial pathogens. Under the five-year contract, Trius will develop novel drugs targeting bacterial DNA Gyrase and Topoisomerase IV, with the aim of optimizing these drugs for...

2008-10-20 09:00:42

NEW HAVEN, Conn., Oct. 20 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that it will present a poster entitled "A Phase 2 Study Comparing Two Doses of Radezolid to Linezolid in Adults with Uncomplicated Skin and Skin Structure Infections (uSSSI)" at the 2008 ICAAC/IDSA Joint Meeting in...

2008-10-20 03:00:08

Basel, Switzerland, October 20, 2008 - New data on Basilea's late-stage anti-infectives ceftobiprole and isavuconazole will be presented at the upcoming joint meeting of the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA) in Washington DC. A series of more than twenty presentations related to ceftobiprole, a broad-spectrum anti-MRSA cephalosporin antibiotic, will be discussed at ICAAC/IDSA. The...

2008-10-20 00:00:08

SAN DIEGO, Oct. 20 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing "Best-in-Class" drugs for the treatment of serious bacterial infections, announced today that the results of multiple studies on its lead program, TR-701, and its other pipeline programs will be presented in eighteen presentations at the upcoming joint Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Diseases Society of America (IDSA) meeting in...

2008-10-14 18:00:21

Targanta Therapeutics Corporation (Nasdaq: TARG) announced today that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee will review the Company's New Drug Application (NDA) for oritavancin on November 19, 2008. Targanta submitted the NDA in February to obtain approval for oritavancin for the treatment of complicated skin and skin structure infection (cSSSI) caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus, or...

2008-10-14 09:00:45

BOSTON, Oct. 14 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced the Company's lead product, amadacycline, formerly PTK 0796, a first-in-class aminomethylcycline, will be the subject of a Late Breaker poster presentation at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). ICAAC will be held in Washington, D.C. from October 25 - October 28, 2008. More information on the poster session at ICAAC: Sunday, October 26, 12:15 - 1:15 pm EST...

2008-10-01 03:00:07

By Maranich, Ashley M Rajnik, Michael ABSTRACT Although vancomycin-resistant Enterococcus infection of the central nervous system is not common, this organism is becoming an increasing problem in nosocomial infections. We report a 17- month-old male infant with an externalized ventricular peritoneal shunt secondary to infection who subsequently developed a vancomycin- resistant Enterococcus faecium ventriculitis. This infection was successfully treated with a 28-day course of linezolid...

2008-09-25 12:00:43

Arpida, a biopharmaceutical company, has completed enrollment in the Phase II 'intravenous-to-oral' switch trial with oral iclaprim in patients with complicated skin and skin structure infections. The trial was designed as a multi-centre, double-blind comparative study. Patients suffering from complicated skin and skin structure infections (cSSSI) received intravenous (IV) vancomycin for the first two days of treatment and were then randomized to either continue to receive IV vancomycin or...

2008-09-22 12:00:38

Trius Therapeutics has initiated a Phase II testing of the oral form of its second-generation oxazolidinone antibacterial drug TR-701. The multicenter trial will test the efficacy, safety and tolerability of once-daily doses of 200, 300 and 400mg of TR-701 in complicated skin and skin structure infections (cSSSI) for five to seven days of treatment. The study follows the recently completed two-part Phase I study that tested the safety, tolerability and pharmacokinetics of TR-701 in single...

2008-09-22 09:00:58

MALVERN, Penn. and WALTHAM, Mass., Sept. 22 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that over 80 percent of surveyed hospital physicians estimate that if approved, Basilea/Johnson & Johnson's ceftobiprole will steal, on average, nearly a third of Pfizer's Zyvox patient share in the treatment of nosocomial pneumonia. In addition, several product profiles that are analogous to ceftobiprole and other antibiotics were presented to physicians to see how...


Latest linezolid Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »